Dechra is a company with a track record of growth and we are delivering on our strategy. Our total revenue of £247.6m in 2016 represents a 21.7% growth on the previous year. Breaking this down further there has been 6.0% organic growth, 2.2% from new products, 3.0% as a result of geographical expansion and 10.5% from acquisition.
Our key areas of expertise span endocrinology, dermatology, cardiology, water soluble powder products and injectable antibiotics, anaesthetics and analgesics, equine medicine and diet and nutrition. Our major products include: